Treatment Comparison for Medial Femoral Condyle Subchondral Cystic Lesions and Prognosis in Yearling Thoroughbred Racehorse Prospects.
Authors: Pérez-Nogués Marcos, Manso-Díaz Gabriel, Spirito Michael, López-Sanromán Javier
Journal: Animals : an open access journal from MDPI
Summary
Subchondral cystic lesions of the medial femoral condyle are commonly identified in Thoroughbred yearlings at sales and surveys, yet optimal management remains unclear. Pérez-Noguès and colleagues followed 182 treated yearlings between 2014 and 2020, comparing four intervention approaches (intralesional corticosteroid injection, arthroscopic debridement, translesional screw fixation, and bioabsorbable hydroxyapatite implantation) against 154 unaffected maternal siblings to determine effects on racing soundness and economic value. Treated horses achieved significantly lower auction prices than their unaffected siblings, and only 59% raced compared to 74% of controls; larger lesions particularly compromised the likelihood of racing and 2-year-old earnings. The bioabsorbable implant group demonstrated superior longevity, with a median of seven starts as 3-year-olds versus three starts in the arthroscopic debridement group. For practitioners involved in sale preparation and pre-purchase evaluation, these findings suggest that whilst any SCL carries a prognosis penalty, implant-based reconstruction appears to offer superior career longevity over simple debridement, and lesion width should feature prominently in clinical counselling and purchase decision-making.
Read the full abstract on PubMed
Practical Takeaways
- •SCL in the medial femoral condyle significantly impacts racing prospects and economic value—treated horses fetch lower auction prices and have reduced race-starting rates compared to unaffected siblings
- •Lesion size matters: wider cysts have worse prognosis for racing starts and earnings, so accurate radiographic assessment is essential for decision-making
- •Treatment choice influences long-term outcomes: bioabsorbable composite implant placement appears superior to arthroscopic debridement for 3-year-old racing frequency, warranting consideration in treatment selection
Key Findings
- •Treated yearlings had significantly lower auction prices and 59% started in races versus 74% of unaffected siblings
- •Wider SCL negatively affected chances to race start and 2-year-old earnings
- •Bioabsorbable implant treatment resulted in 7 starts as 3-year-olds compared to 3 starts with drill debridement
- •Mares and right stifle lesions were significantly overrepresented in the treated population